6月26日早间，信达生物发布公告，公司与联席配售代理订立配售协议，公司同意委任联席配售代理， 而联席配售代理同意作为配售代理行事，作为公司的代理根据配售协议所载的条款并在其条件规限下， 促使承配人（否则自行）以配售价购买5500万股配售股份。 信达生物还表示，配售事项所得款项总额预期约为43.1亿港元；扣除所有相关成本及开支，包括佣金及 征费后，所得款项净额将约为42.65亿港元。 当日信达生物低开，随后震荡下行，一度跌超5%，截至收盘报78.6港元/股，下跌4.61%。 针对此次配售新股的原因以及所得款项的用途，信达生物表示，锚定"成长为国际一流的生物制药企 业"的长期愿景，公司正步入全球创新的新成长周期。创新管线的全球化布局已逐步成为公司潜在的重 要增长引擎，并展现出其核心竞争力。 信达生物认为，本次配售事项将更好地支持公司的全球化布局，并赋予本公司在管线开发上更多支持和 灵活性。这将有助于充分挖掘并加速实现公司丰厚管线的价值潜能，为公司与股东创造可持续的长期回 报。因此，董事认为，配售事项符合本集团及股东的整体利益。 本次配售事项所得净款项中，约90%（即约38.39亿港元）用于推进公司临床及临床前重点 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-036 上海君实生物医药科技股份有限公司 关于完成根据一般授权配售新 H 股的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海君实生物医药科技股份有限公司（以下简称"本公司"）于 2025 年 6 月 13 日披露了《上海君实生物医药科技股份有限公司关于根据一般授权配售新 H 股的公告》（公告编号：临 2025-034，以下简称"配售公告"），内容有关本 公司配售 41,000,000 股新 H 股（以下简称"配售事项"）。除文义另有所指外， 本公告所用所有词汇与配售公告所界定者具有相同涵义。 一、 完成配售事项 董事会欣然宣布，配售协议所载的所有配售事件先决条件已达成（包括香港 联交所批准配售股份上市及买卖），配售事项已于 2025 年 6 月 20 日完成（以下 简称"配售完成"）。 经独家配售代理通知，已根据配售协议中的条件及条款按每股 H 股 25.35 港 元的配售价格向符合条件的承配人成功配售合计 41,000,000 股 H 股配售 ...

Core Viewpoint - Junshi Bioscience has announced a new H-share placement, which has led to a decline in its stock prices in both A-share and Hong Kong markets, indicating market concerns about the company's financial strategies and performance [1][2]. Group 1: Stock Performance - On June 17, Junshi Bioscience's A-share closed at 34.64 CNY, down 3.10%, while its Hong Kong share closed at 23.50 HKD, down 9.09% [1]. - The stock had previously closed at 36.08 CNY and 25.65 HKD on June 13, reflecting a decline of 6.65% and 10.47% respectively [1]. Group 2: H-share Placement Details - The company plans to issue 41,000,000 new H-shares at a price of 25.35 HKD per share, which represents approximately 18.70% of the total issued H-shares and 4.16% of the total issued shares as of the announcement date [2]. - The expected total proceeds from the placement are approximately 1,039 million HKD, with a net amount of about 1,026 million HKD after deducting commissions and estimated expenses [2]. Group 3: Use of Proceeds - The company intends to allocate 70% of the net proceeds from the placement towards innovative drug research and development, including projects like JS207, JS212, and JS213 [3]. - The remaining 30% of the net proceeds will be used to supplement working capital and other general corporate purposes [3]. Group 4: Historical Financial Performance - Since its listing on July 15, 2020, Junshi Bioscience has experienced a significant decline in stock price, with the highest price reaching 220.40 CNY on the first trading day [5][6]. - The company has not declared any dividends or stock transfers since its IPO, and its cumulative fundraising from two rounds amounts to 8.613 billion CNY [7]. - The net profit attributable to shareholders has been negative for several years, with figures ranging from -1.35 billion CNY in 2016 to -12.81 billion CNY in 2024 [7].